Literature DB >> 24012714

QSAR modeling of aromatase inhibitory activity of 1-substituted 1,2,3-triazole analogs of letrozole.

Chanin Nantasenamat1, Apilak Worachartcheewan, Supaluk Prachayasittikul, Chartchalerm Isarankura-Na-Ayudhya, Virapong Prachayasittikul.   

Abstract

Aromatase is an estrogen biosynthesis enzyme belonging to the cytochrome P450 family that catalyzes the rate-limiting step of converting androgens to estrogens. As it is pertinent toward tumor cell growth promotion, aromatase is a lucrative therapeutic target for breast cancer. In the pursuit of robust aromatase inhibitors, a set of fifty-four 1-substituted mono- and bis-benzonitrile or phenyl analogs of 1,2,3-triazole letrozole were employed in quantitative structure-activity relationship (QSAR) study using multiple linear regression (MLR), artificial neural network (ANN) and support vector machine (SVM). Such QSAR models were developed using a set of descriptors providing coverage of the general characteristics of a molecule encompassing molecular size, flexibility, polarity, solubility, charge and electronic properties. Important physicochemical properties giving rise to good aromatase inhibition were obtained by means of exploring its chemical space as a function of the calculated molecular descriptors. The optimal subset of 3 descriptors (i.e. number of rings, ALogP and HOMO-LUMO) was further used for QSAR model construction. The predicted pIC₅₀ values were in strong correlation with their experimental values displaying correlation coefficient values in the range of 0.72-0.83 for the cross-validated set (QCV) while the external test set (Q(Ext)) afforded values in the range of 0.65-0.66. Insights gained from the present study are anticipated to provide pertinent information contributing to the origins of aromatase inhibitory activity and therefore aid in our on-going quest for aromatase inhibitors with robust properties.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aromatase; Breast cancer; Chemical space; Letrozole; QSAR; Structure–activity relationship; Triazole

Mesh:

Substances:

Year:  2013        PMID: 24012714     DOI: 10.1016/j.ejmech.2013.08.015

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation.

Authors:  Michele De Luca; Maria Antonietta Occhiuzzi; Bruno Rizzuti; Giuseppina Ioele; Gaetano Ragno; Antonio Garofalo; Fedora Grande
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 2.  Towards understanding aromatase inhibitory activity via QSAR modeling.

Authors:  Watshara Shoombuatong; Nalini Schaduangrat; Chanin Nantasenamat
Journal:  EXCLI J       Date:  2018-07-20       Impact factor: 4.068

3.  Probing the origins of aromatase inhibitory activity of disubstituted coumarins via QSAR and molecular docking.

Authors:  Apilak Worachartcheewan; Naravut Suvannang; Supaluk Prachayasittikul; Virapong Prachayasittikul; Chanin Nantasenamat
Journal:  EXCLI J       Date:  2014-12-08       Impact factor: 4.068

4.  Origin of aromatase inhibitory activity via proteochemometric modeling.

Authors:  Saw Simeon; Ola Spjuth; Maris Lapins; Sunanta Nabu; Nuttapat Anuwongcharoen; Virapong Prachayasittikul; Jarl E S Wikberg; Chanin Nantasenamat
Journal:  PeerJ       Date:  2016-05-12       Impact factor: 2.984

5.  3D-QSAR study of steroidal and azaheterocyclic human aromatase inhibitors using quantitative profile of protein-ligand interactions.

Authors:  Sehan Lee; Mace G Barron
Journal:  J Cheminform       Date:  2018-01-18       Impact factor: 5.514

6.  Towards an Understanding of the Mode of Action of Human Aromatase Activity for Azoles through Quantum Chemical Descriptors-Based Regression and Structure Activity Relationship Modeling Analysis.

Authors:  Chayawan Chayawan; Cosimo Toma; Emilio Benfenati; Ana Y Caballero Alfonso
Journal:  Molecules       Date:  2020-02-08       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.